Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check2 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check24 days agoChange DetectedThe website has updated its contact information for several principal and sub-investigators, including the addition of new contacts and the removal of previous ones, while also noting a revision update from v2.13.3 to v2.14.0.SummaryDifference9%
- Check53 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.0%
- Check60 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the location details.SummaryDifference2%
- Check74 days agoChange DetectedSeveral key URLs related to genetics, lung cancer, and medical resources have been removed, indicating a potential shift in focus or resource availability on the website.SummaryDifference3%
Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.